Novavax Inc (NVAX)
$4.03 0.05 (1.26%)
19:37 EST NVAX Stock Quote Delayed 15 Minutes
Previous Close $4.03
Market Cap 1.54B
PE Ratio -6.61
Volume (Avg. Vol.) 1.37M
Day's Range 3.94 - 4.09
52-Week Range 0.34 - 8.45
Dividend & Yield N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
- From InvestorPlace
- From the Web
For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.
Novavax news for Thursday concerning an accelerated approval pathway for one of the company's drugs has NVAX stock soaring higher.
With the major indices showing signs of hesitancy, now is an ideal time to consider lesser-known but viable cheap stocks.
Novavax stock is plunging on Thursday after failing a Phase 3 study. That sets up a breakdown instead of a breakout in NVAX stock.
The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut. Com....
As one of the 657 companies in the GICS Health Technology sector Novavax Inc (NASDAQ:NVAX) is a constituent of the 337 company Biotechnology GICS industry group within this sector. NVAX has a market value of $0.6 billion which is in the top half of its industry group. Portfolio Grader's current ranking for NVAX puts it 107 among the 337 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 213 among the 657 companies in the sector, and number 1,498 in the nearly 5,000 company Portfolio Grader universe.
Novavax Inc (NASDAQ:NVAX) ranks in the upper half of its industry group, Biotechnology, and in the upper half of its sector group, Health Technology, with a market value of $0.4 billion. From an investment attractiveness vantage point, NVAX is ranked in the top half of the sector with a ranking of 264 among the 656 companies in the sector; the ranking for NVAX by Portfolio Grader places it 127 among the 337 companies in this industry group, giving it an above-average position and number 1,942 in the 5000 company Portfolio Grader company universe.
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Biotechs like NVAX, GERN and RGLS have made a name for themselves for all the wrong reasons, but they also have a chance at redemption.
Novavax (NVAX) stock is an absolute wild card, but it sure is scrappy. Regardless, it's bound to see a shift in analyst expectations soon.
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
3 Stocks to Watch Friday: Novavax, Inc. (NVAX), Oracle Corporation (ORCL) and Unilever plc (ADR) (UL)
Novavax (NVAX) is on its last legs, Oracle (ORCL) is dropping and Unilever (UL) is in early discussions to buy out Jessica Alba's Honest Co.
The following stocks were moving the Manufacturing sector today.
This week, the overall grades of 23 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Novavax, Inc. (NASDAQ:NVAX) is leading the biotech charge downward today on dismal earnings that left investors questioning the bull case.
Navellier RatingsPowered by Portfolio Grader